Evidence map›Paper›PMID 26285691›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2016

Nitric Oxide Contributes to Vasomotor Tone in Hypertensive African Americans Treated With Nebivolol and Metoprolol.

Robert B Neuman, Salim S Hayek, Joseph C Poole, Ayaz Rahman, Vivek Menon, Nino Kavtaradze, David Polhemus, Emir Veledar, David J Lefer, Arshed A Quyyumi

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01049009 (The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01049009 phase4completednot on this map

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

TypeinterventionalSponsorEmory UniversityRan2009 to 2012Enrolled91ConditionsHigh Blood PressureArmsNebivolol, Metoprolol XL
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Strategies of Pathogens to Escape from NO-Based Host Defense.Antioxidants (Basel, Switzerland) · 2022
    Review
  6. Race and sex differences in cardiovascular autonomic regulation.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020
    Review
  7. Article
  8. Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure.Mayo Clinic proceedings. Innovations, quality & outcomes · 2019
    Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Robert B NeumanDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
Salim S HayekDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.ORCID http://orcid.org/0000-0003-0180-349X
Joseph C PooleDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
Ayaz RahmanDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
Vivek MenonDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
Nino KavtaradzeDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
David PolhemusDepartment of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, LA.
Emir VeledarDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
David J LeferDepartment of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, LA.
Arshed A QuyyumiDivision of Cardiology, Emory University School of Medicine, Atlanta, GA.
Emory University · USLouisiana State University Health Sciences Center New Orleans · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Functional Cardio-MetabolomicsP20HL113452 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L, TANG, WAI HONG WILSON · 2012 to 2016
$4.8M
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NHLBI NIH HHS P20 HL113452
6 · The paper itself

Abstract

Endothelial dysfunction is more prevalent in African Americans (AAs) compared with whites. The authors hypothesized that nebivolol, a selective β1 -antagonist that stimulates nitric oxide (NO), will improve endothelial function in AAs with hypertension when compared with metoprolol. In a double-blind, randomized, crossover study, 19 AA hypertensive patients were randomized to a 12-week treatment period with either nebivolol 10 mg or metoprolol succinate 100 mg daily. Forearm blood flow (FBF) was measured using plethysmography at rest and after intra-arterial infusion of acetylcholine and sodium nitroprusside to estimate endothelium-dependent and independent vasodilation, respectively. Physiologic vasodilation was assessed during hand-grip exercise. Measurements were repeated after NO blockade with L-N(G) -monomethylarginine (L-NMMA) and after inhibition of endothelium-derived hyperpolarizing factor (EDHF) with tetraethylammonium chloride (TEA). NO blockade with L-NMMA produced a trend toward greater vasoconstriction during nebivolol compared with metoprolol treatment (21% vs 12% reduction in FBF, P=.06, respectively). This difference was more significant after combined administration of L-NMMA and TEA (P<.001). Similarly, there was a contribution of NO to exercise-induced vasodilation during nebivolol but not during metoprolol treatment. There were significantly greater contributions of NO and EDHF to resting vasodilator tone and of NO to exercise-induced vasodilation with nebivolol compared with metoprolol in AAs with hypertension.

Indexed as

Black or African AmericanCross-Over StudiesDouble-Blind MethodForearmHumansHypertensionMetoprololMuscle HypotoniaNebivololNitric OxidePlethysmographyRegional Blood FlowVasodilationVasomotor SystemMetoprololNebivololNitric Oxide

Identifiers

PMID26285691
PMCPMC4760906
OpenAlexW2100127875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.